2013

Skip to Main Content

Order by

B01 – The Genomic Landscape of Small Intestine Neuroendocrine Tumors

Published in 2013 Listed under Basic Science

Banck

B02 – Somatic Mutations in Inherited Pheochromocytomas and Paragangliomas

Published in 2013 Listed under Basic Science

Fishbein

B03 – A Multi-Gene Transcript Blood Molecular Signature for the Detection and Treatment of Gut Neuroendocrine Tumors

Published in 2013 Listed under Basic Science

Kidd

B04 – Specific Glycogen Synthase Kinase-3 Inhibition Suppresses Growth and Reduces the Neuroendocrine Tumor Markers in Neuroblastoma Cells

Published in 2013 Listed under Basic Science

Kunnimalaiyaan

B05 – Gastric Inhibitory Polypeptide Receptor (GIPR): A Future Alternative to Somatostatin Type 2 Receptor Imaging and Treatment in Neuroendocrine Tumors?

Published in 2013 Listed under Basic Science

Sherman

B06 – PI3K-AKT-mTOR Pathway Disregulation and its Correlation with Clinical Outcome in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

Published in 2013 Listed under Basic Science

Spada

B07 – A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Recapitulates Hallmark Features of the Disease

Published in 2013 Listed under Basic Science

Wang

B08 – Aberrant Activation of DNA methyltransferase 1 (DNMT1) Mediated Global DNA Methylation and Implicates Sox/Wnt/Î²-Catenin Signaling Pathway in the Multiple Endocrine Neoplasm Type 1 (MEN1) Syndrome

Published in 2013 Listed under Basic Science

Yuan

C01 – Czech Registery of Neuroendocrine Neoplasms (NEN)

Published in 2013 Listed under Clinical

Barkmanova

C02 – A Systematic Literature Review on the Efficacy and Safety of Octreotide Long-Acting Repeatable Used at Higher than FDA-Approved Doses and/or Frequencies for Treatment of Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Broder

C03 – Octreotide LAR in Patients with Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Series

Published in 2013 Listed under Clinical

Byron

C04 – Lanreotide Autogel Significantly Improves Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors: Results of the CLARINET Study

Published in 2013 Listed under Clinical

Caplin

C05 – Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma

Published in 2013 Listed under Clinical

Fishbein

C06 – Cumulative Safety Experience of Telotristat Etiprate in Clinical Trials Supports Advancement to Phase 3

Published in 2013 Listed under Clinical

Fleming

C07 – Unusual Case of a Hormone-Secreting SDHC Head and Neck Paraganglioma

Published in 2013 Listed under Clinical

Ghayee

C08 – Moving 68Ga-labeled DOTA PET Imaging Agents Towards Approval

Published in 2013 Listed under Clinical

Graham

C09 – A Phase I Study of Imatinib, Dacarbazine, and Capecitabine in Advanced Endocrine Cancers

Published in 2013 Listed under Clinical

Halperin

C10 – Clinical Presentation and Management of Patients with Bone Metastases (BMet) from Neuroendocrine Tumors (NETs): Pooled Results from Two Institutional Databases

Published in 2013 Listed under Clinical

Keiser

C11 – SDHB Pheochromocytoma and Paraganglioma Penetrance in a United States Population: An NIH Study

Published in 2013 Listed under Clinical

King

C12 – Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Kulke

C13 – Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Carcinoid Tumor and Octreotide-Refractory Diarrhea

Published in 2013 Listed under Clinical

Kulke

C14 – Comparison of 68Ga-DOTATATE (Ga) PET/CT with 111In-Octreotide (Octreoscan) SPECT in Somatastatin Positive Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Kumar

C15 – Patterns of Hepatic Metastases in Midgut Carcinoid: Diffuse Micrometastases and Disease Recurrence

Published in 2013 Listed under Clinical

Liu

C16 – Neuroendocrine Tumors Arising in Meckel's Diverticula: Frequency of Advanced Disease Warrants Aggressive Management

Published in 2013 Listed under Clinical

Lorenzen

C17 – 5-Fluorouracile/Capecitabine and Oxaliplatin (FOLFOX/XELOX) Suitable Treatments for Progressing G1-G2 Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Marconcini

C18 – Neuroendocrine Tumors Treated with Lanreotide After First Line Treatment with Octreotide LAR: A Single Center Experience

Published in 2013 Listed under Clinical

Marconcini

C19 – Recurrence After Complete Resection of Gastrointestinal (GNET) or Pancreatic Neuroendocrine Tumors (PNET): Single Center Analysis

Published in 2013 Listed under Clinical

Marconcini

C20 – Single Center Experience of Everolimus (Ev) Treatment in Pretreated Metastatic Well Differentiated Gastrointestinal (GNET) and Pancreatic Neuroendocrine Tumors (PNET)

Published in 2013 Listed under Clinical

Marconcini

C21 – Somatostatine Analogs (SSA) Treatment in Well Differentiated Gastroenteropancreatic NeuroendocrineTumors (GEP-NET): A Single Centre Experience

Published in 2013 Listed under Clinical

Marconcini

C22 – Association of Urinary Bladder Paragangliomas with Germline Mutations in the SDHB and VHL Genes

Published in 2013 Listed under Clinical

Martucci

C23 – Gallium-68 DOTATOC PET-CT for Localization of Primary Tumor in Patients with Metastatic Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Menda

C24 – The Diagnostic Utility of Gallium-68 DOTATOC PET-CT in Patients with Suspected Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Menda

C25 – Tumor Shrinkage in a Patient with Cushing's Disease Treated with Pasireotide: A Clinical Case Report

Published in 2013 Listed under Clinical

Moloney

C26 – Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index For Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki67Counter)

Published in 2013 Listed under Clinical

Neltner

C27 – Safety and Quality-Of-Life (QOL) Assessments in the Open-Label, Multicenter, Phase 3b, Expanded Access Study of Everolimus in Patients with Advanced Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Pavel

C28 – Phase 1 Maximum-Tolerated Dose Study of Pasireotide LAR in Patients with Advanced Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Phan

C29 – Efficacy and Safety of Everolimus in Patients with Advanced Low- or Intermediate-grade Pancreatic Neuroendocrine Tumors Previously Treated with Chemotherapy: A Subgroup Analysis of the RADIANT-3 Trial

Published in 2013 Listed under Clinical

Pommier

C30 – Tumor Expression of VEGFA and Its Receptors and Clinical Outcomes in Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Qian

C31 – A Phase I/II Dose Escalation Study of TKM-080301, a RNAi Therapeutic Directed Against PLK1, in Patients with Advanced Solid Tumors, with an Expansion Cohort of Patients with NET or ACC

Published in 2013 Listed under Clinical

Ramanathan

C32 – Bronchial Carcinoid Tumors: A Single Institution Review

Published in 2013 Listed under Clinical

Ramirez

C33 – Development of AminoMedixTM, a Kidney Protective Agent During Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Cancers

Published in 2013 Listed under Clinical

Ranganthan

C34 – Survival in the Pre- and Post-Octreotide LAR Era in Carcinoid Syndrome Patients

Published in 2013 Listed under Clinical

Ray

C35 – A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)

Published in 2013 Listed under Clinical

Reidy

C36 – MIBG Avidity and Therapy in a Metastatic GI Neuroendocrine Tumor Patient Cohort

Published in 2013 Listed under Clinical

Riff

C37 – Systemic Toxicity after Delayed Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Riff

C38 – Is Renal Toxicity From Y-90 DOTATOC Dependent Upon Dose per PRRT Treatment?

Published in 2013 Listed under Clinical

Sharma

C39 – Tumor Heterogeneity in Small Intestine Neuroendocrine Tumors Metastatic to the Liver

Published in 2013 Listed under Clinical

Shi

C40 – Von Recklinghausen's Disease and Pheochromocytoma: A Ten-Year Experience

Published in 2013 Listed under Clinical

Shinall

C41 – Retrospective Review of Patients with Metastatic High Grade Neuroendocrine Carcinoma of the Pancreas: Memorial Sloan-Kettering Cancer Center Experience (MSKCC)

Published in 2013 Listed under Clinical

Shum

C42 – Capecitabine Plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Tumors (NETs): An Italian Multicenter Retrospective Analysis

Published in 2013 Listed under Clinical

Spada

C43 – Increased Incidence of Second Malignancy in Patients with Neuroendocrine Tumours (NETs) of the Ileum and Colon (MGC)

Published in 2013 Listed under Clinical

Stronge

C44 – Dosing Patterns for Octreotide LAR in Neuroendocrine Tumor (NET) Patients: NCCN NET Outcomes Database

Published in 2013 Listed under Clinical

Strosberg

C45 – Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney

Published in 2013 Listed under Clinical

Subbiah

C46 – A Multicenter Phase II Trial Evaluating Safety and Efficacy of Activity Escalation with 177Lu-DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors, Based on Detailed Dosimetry and Patient Selection

Published in 2013 Listed under Clinical

Sundlov

C47 – Metastatic Recurrent Small Bowel "Carcinoid": The Role of Blood Neuroendocrine Transcript Analysis in Diagnosis and Management

Published in 2013 Listed under Clinical

Teixeira

C48 – 68Ga-DOTATATE PET/CT Imaging for Evaluation of Neuroendocrine Tumors (NET): The Vanderbilt Experience

Published in 2013 Listed under Clinical

Walker

C49 – Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable?

Published in 2013 Listed under Clinical

Wang

C50 – The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors

Published in 2013 Listed under Clinical

Wang

C51 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Published in 2013 Listed under Clinical

Wolin

C52 – A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Published in 2013 Listed under Clinical

Wolin

C53 – Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study

Published in 2013 Listed under Clinical

Yao

C54 – The Immunohistochemical Expression of Islet 1 and PAX8 by Rectal Neuroendocrine Tumors Should be Taken into Account in the Differential Diagnosis of Metastatic Neuroendocrine Tumors of Unknown Primary Origin

Published in 2013 Listed under Clinical

Zhou